shares of Dyadic International Inc (DYAI) on
Dyadic International, Inc. engages in developing a gene expression platform for producing commercial quantities of industrial enzymes and other proteins. The company is headquartered in Jupiter, Florida and currently employs 57 full-time employees. The firm is a global biotechnology company with operations in the United States and the Netherlands. Dyadic uses its technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceuticals and industrial enzymes industries. Its activities relating to selling enzymes focuses on utilizing its fungal strains and associated technologies. In particular, Dyadic uses its Trichoderma and C1 (Myceliopthora thermophila) fungal strains in the production of its industrial enzymes. Dyadic manufactures, purchases, and sells liquid and dry enzyme products to global customers for use within the animal feed, pulp and paper, starch and alcohol, food and brewing, textiles and biofuels industries. The company is focused on biofuels and bio-based chemicals, biopharmaceuticals and industrial products.